Jazz Pharmaceuticals (NASDAQ: JAZZ) reported Q3 EPS of $4.84, $0.09 worse than the analyst estimate of $4.93. Revenue for the quarter came in at $972 million versus the consensus estimate of $969.02 million.

GUIDANCE:

Jazz Pharmaceuticals sees FY2023 EPS of $18.15-$19.00, versus the consensus of $18.66.

For earnings history and earnings-related data on Jazz Pharmaceuticals (JAZZ) click here.